Screener
Kyverna Therapeutics, Inc. KYTX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
| Total other income, net | 1,639 | 2,773 |
| Net loss | (39,728) | (44,635) |
| Other comprehensive loss | ||
| Unrealized loss on available-for-sale marketable securities, net | (193) | (106) |
| Total other comprehensive loss | (193) | (106) |
| Net loss and other comprehensive loss | $(39,921) | $(44,741) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s net income?
- Kyverna Therapeutics, Inc. (KYTX) reported net income of -$39.73M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s net income changed year-over-year?
- Kyverna Therapeutics, Inc.'s net income increased by 11.0% year-over-year, from -$44.64M to -$39.73M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s net income?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s net income has grown at a 63.5% compound annual growth rate (CAGR), from -$60.37M to -$161.31M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Kyverna Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude